Skill: Antitrust Transaction Structure Analysis

1. Subject-matter triage

• Treat the assignment as an antitrust deal-review memo, not a generic diligence summary.
• Identify whether the source set includes merger agreement drafts, board decks, banker materials, emails, schedules, and regulatory strategy materials.
• Separate transactional structure issues from substantive competition issues, then connect them back to clearance risk and closing mechanics.
• If multiple jurisdictions, business lines, or product overlaps are present, analyze each as a distinct clearance track rather than collapsing them into one global assessment.

2. Failure modes the skill is correcting

• The analysis stops at “antitrust risk exists” without tying that risk to a specific remedy posture, filing path, or closing consequence.
• The analysis ignores the practical force of a reverse termination fee and whether it is large enough to change behavior rather than merely allocate downside.
• The analysis treats a divestiture cap, remedy carve-out, or consent limitation as boilerplate instead of testing whether it weakens the buyer’s clearance commitment.
• The analysis misses whether the outside date leaves enough runway for clearance review, second requests, remedy negotiation, or post-clearance waiting periods.
• The analysis overlooks internal materials that frame the deal as a pricing, capacity, market-power, or competitor-removal story and therefore require careful document handling.
• The analysis mentions overlap but does not connect overlap to likely unilateral, coordinated, or vertical theories of harm.
• The analysis identifies concerns but does not end with concrete recommendations on filings, term changes, preservation, and remedy strategy.

3. Legal frameworks / domain conventions that apply

• Use the relevant merger-control standard for each jurisdiction implicated by the deal; anchor the analysis in the governing competition statute and agency practice for that forum.
• For U.S. review, frame the substantive analysis under Section 7 of the Clayton Act and the Hart-Scott-Rodino Act filing regime where applicable; for other jurisdictions, use the local merger-control statute and clearance test.
• Assess concentration, overlap, and competitive effects using the standard merger-screen framework: relevant market, shares, concentration, entry, diversion, and likely remedy path.
• Treat a hell-or-high-water commitment as meaningful only if it obligates the buyer to pursue and accept commercially reasonable remedies needed for clearance; remedy caps, asset exclusions, or “no structural divestiture” language may materially dilute it.
• Evaluate a reverse termination fee as an incentive device: it should be measured against the transaction’s risk profile and closing economics, not treated as sufficient merely because it exists.
• Test the outside date against expected agency timing, second-request exposure, litigation risk, and any post-clearance waiting period or local sequencing requirement.
• Treat internal documents discussing pricing power, reduced competition, market control, customer capture, or competitor removal as hot documents relevant to intent and effects.
• Treat non-compete and similar retention restrictions as part of the competition analysis where departing personnel or management could compete post-closing.
• Use merger-specific remedy concepts: divestiture buyer viability, fix-it-first feasibility, conduct remedy limits, and whether the proposed buyer restores competitive conditions.

4. Analytical scaffolds

1. Map the transaction
   • Identify the parties, business lines, products, geography, and review jurisdictions.
   • Enumerate each overlap, adjacency, and customer-facing interaction before analyzing effects.
2. Assess substantive antitrust risk
   • Define the likely relevant market(s) at the level supported by the documents.
   • Analyze concentration, diversion, customer switching, capacity, and entry.
   • State the likely theory of harm for each overlap: unilateral effects, coordinated effects, foreclosure, or information-based concerns.
3. Test the documentary record for hot issues
   • Review board decks, banker books, management presentations, emails, and draft strategy materials for competition-sensitive language.
   • Flag each item by document type and why it is sensitive.
   • Recommend preservation, legal hold, and privilege review steps where the record suggests antitrust intent risk.
4. Analyze deal-protection mechanics
   • Evaluate whether the hell-or-high-water covenant is broad enough to require meaningful remedy pursuit.
   • Check whether any remedy cap, carve-out, or buyer consent right undermines the covenant.
   • Assess whether the reverse termination fee is large enough to create real clearance incentives.
   • Test whether the outside date accommodates the likely clearance path.
5. Evaluate remedies and filing strategy
   • Identify whether divestiture, conduct commitments, or behavioral undertakings are likely to be requested.
   • Assess potential remedy buyers for capability, independence, and operational fit.
   • Determine whether filings should be made early, simultaneously, sequentially, or with a hold-separate strategy.
6. Close each issue with consequences
   • For every issue, tie the concern to a source-document metric or transactional fact, cross-reference the clause or exhibit that affects it, and state the closing, regulatory, or litigation consequence.
7. Assign severity consistently
   • Use a defined ordinal severity scale throughout the memo and apply it uniformly to each issue.

5. Vertical / structural / temporal relationships

• Identify how the merger agreement, disclosure schedules, internal strategy materials, and regulatory communications interact.
• If one provision limits another, explain the hierarchy in practical terms: e.g., a remedy covenant may be narrowed by a cap, timing gate, or consent standard.
• Track sequencing risk: signing, filing, waiting period, second request, remedy discussions, and closing should be analyzed in temporal order.
• If the record contains multiple products, regions, or clearance authorities, analyze them separately first and then state the combined closing timetable.
• Distinguish pre-signing risk flags from post-signing obligations so the memo does not conflate diligence concerns with covenants.

6. Output structure conventions

• Begin with a short executive summary stating the overall antitrust risk level and the likely clearance posture.
• Use a clear severity scale near the front of the memo and apply it to each issue consistently.
• Organize the body in a conventional issues-memo shape:
  • Transaction overview and review scope
  • Competitive overlap and market context
  • Hot documents and document-handling risks
  • Deal-protection and closing-condition analysis
  • Remedies and filing strategy
  • Recommended actions
• For each issue, include:
  • Severity
  • Legal basis with the controlling authority named
  • The relevant factual trigger from the documents
  • The interaction with another clause, schedule, or document
  • The downstream consequence for clearance, timing, or economics
• Do not state antitrust conclusions in conclusory form without naming the governing statute, regulation, or doctrinal standard supporting them.
• End with a Recommended Actions block that assigns each action to a responsible role and ties it to a transaction or regulatory milestone.
• Include document-preservation and privilege-review steps whenever internal materials suggest competition-sensitive intent.
• If the source set supports more than one filing path or remedy posture, list each path separately and compare the tradeoffs rather than selecting a single default.